The Size of the Asia-Pacific Biochips Market is valued at USD 2.57 billion in 2019 and Expected to Reach at a CAGR of 22.94%, to reach USD 7.21 billion by 2024 during the forecast period 2019-2024.
The medicinal importance of miniaturised biological microarray chips, generally known as biochips, has produced a transforming effect on the global healthcare industry. The extensive variety of biochip applications and products have propelled the growth of the market at an extraordinary level.
Biochip products consist of microarrays of biochemical particles, which are assembled on a silicon or glass plate. These devices have functions in gene sequencing, proteomics, genomics, clinical diagnosis, and drug discovery.
The growth of the Asia-Pacific Biochips market is mainly due to factors such as rise in the utilization of personalized medicine, demand for high speed diagnostics and increasing government funding. In addition, growing healthcare awareness is also boosting the growth of the biochips market. However, inadequate technical awareness related to biochips, low acceptance due to high cost and accessibility to alternate technologies are some of the major factors limiting the growth of the market in this region.
Asia Pacific Biochips Market segmented and sub-segmented into the following categories.
On the Basis of Region, The Asia-Pacific region is projected to grow at the highest CAGR during the forecast period due to various reasons such as easy access to the latest technologies, a large patient pool, and promising government schemes. China and India are projected to be the fastest growing markets in this region.
Key Market Participants leading the Asia Pacific Biochips Market Profiled in the Report are Agilent Technologies Inc., Fluidigm Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., GE Healthcare, Cepheid Inc., Illumina Inc., and Thermo Fisher Scientific Inc.,
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 DNA Chips
5.1.2.1 SNP Genotyping
5.1.2.2 Genomics
5.1.2.3 Agricultural Biotechnology
5.1.2.4 Gene Expression
5.1.2.5 Cancer Diagnosis & Treatment
5.1.2.6 Drug Discovery
5.1.2.7 Others
5.1.3 Lab-On-A-Chip
5.1.3.1 Clinical Diagnostics
5.1.3.2 IVD & POC
5.1.3.3 Drug Discovery
5.1.3.4 Genomics
5.1.3.5 Proteomics
5.1.4 Protein Chips
5.1.4.1 Expression Profiling
5.1.4.2 High-Throughput Screening
5.1.4.3 Proteomics
5.1.4.4 Diagnostics
5.1.4.5 Drug Discovery
5.1.5 Other types
5.1.6 Y-o-Y Growth Analysis, By Type
5.1.7 Market Attractiveness Analysis, By Type
5.1.8 Market Share Analysis, By Type
5.2 End User
5.2.1 Introduction
5.2.2 Hospitals and Diagnostics Centers
5.2.3 Biotechnology and Pharmaceutical Companies
5.2.4 Academic & Research Institutes
5.2.5 Y-o-Y Growth Analysis, By End User
5.2.6 Market Attractiveness Analysis, By End User
5.2.7 Market Share Analysis, By End User
5.3 Fabrication Technology
5.3.1 Introduction
5.3.2 Microfluidics
5.3.3 Microarrays
5.3.4 Y-o-Y Growth Analysis, By Fabrication Technology
5.3.5 Market Attractiveness Analysis, By Fabrication Technology
5.3.6 Market Share Analysis, By Fabrication Technology
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By End User
6.1.3.4 By Fabrication Technology
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By End User
6.1.4.4 By Fabrication Technology
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By End User
6.1.5.4 By Fabrication Technology
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Athersys
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 StemCells
8.3 Cryo Cell International
8.4 Geron Corporation
8.5 Mesoblast
8.6 Aastrom Biosciences
8.7 Celgene Corporation
8.8 Invitrogen
8.9 Cytori Therapeutics
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
